Evidence map›Paper›PMID 39996747›Full record

ArticleCells2025

Tumor-Associated Macrophage (TAM)-Related Cytokines, sCD163, CCL2, and CCL4, as Novel Biomarkers for Overall Survival and Time to Treatment in Waldenstrom's Macroglobulinemia: Emphasis on Asymptomatic WM.

Alexandros Gkiokas, Mavra Papadatou-Gigante, Annita Ioanna Gkioka, Aspasia Koudouna, Thomai M Tryfou, Alexandros Alexandropoulos, Vassiliki Bartzi, Nikolitsa Kafasi, Marie-Christine Kyrtsonis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alexandros GkiokasHematology Section, First Department of Propaedeutic Internal Medicine, Laikon Hospital, Faculty of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Mavra Papadatou-GiganteHematology Section, First Department of Propaedeutic Internal Medicine, Laikon Hospital, Faculty of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Annita Ioanna GkiokaHematology Section, First Department of Propaedeutic Internal Medicine, Laikon Hospital, Faculty of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0009-0002-1599-5509
Aspasia KoudounaHematology Section, First Department of Propaedeutic Internal Medicine, Laikon Hospital, Faculty of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0009-0001-3284-3710
Thomai M TryfouHematology Section, First Department of Propaedeutic Internal Medicine, Laikon Hospital, Faculty of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Alexandros AlexandropoulosHematology Section, First Department of Propaedeutic Internal Medicine, Laikon Hospital, Faculty of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Vassiliki BartziHematology Section, First Department of Propaedeutic Internal Medicine, Laikon Hospital, Faculty of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Nikolitsa KafasiImmunology Department, Laikon Hospital, 11527 Athens, Greece.
Marie-Christine KyrtsonisHematology Section, First Department of Propaedeutic Internal Medicine, Laikon Hospital, Faculty of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Waldenstrom's Macroglobulinemia (WM) is a heterogeneous disease, and the majority of patients tend to have a long course. Nevertheless, it is imperative to detect patients who have a high risk of progression and who benefit from closer follow-up. Many recent studies have displayed the CD163-positive tumor-associated macrophages (TAMs) contribution in the pathogenesis of various hematological neoplasms and solid tumors. Soluble CD163 (sCD163) can be measured in serum, along with other TAM-chemoattractant cytokines, such as CCL2 and CCL4, and their levels are used to determine macrophage activation. In the current study, we investigated the correlation between sCD163, CCL2, and CCL4, with parameters of WM progression and survival. Out of a total of 204 WM patients, serum sCD163, CCL2, and CCL4 were measured in 75, 64, and 65 patients' frozen sera at diagnosis, along with 30 healthy individuals (HIs) using an enzyme-linked immunosorbent assay (ELISA). We achieved to demonstrate that shorter Time to Treatment (TTT) was observed in 2 years and 7 years intervals in all patients with a ratio of CD163/CCL4 above median (

Indexed as

Antigens, CDAntigens, Differentiation, MyelomonocyticBiomarkers, TumorChemokine CCL2Chemokine CCL4Receptors, Cell SurfaceTumor-Associated MacrophagesWaldenstrom MacroglobulinemiaAdultAgedAged, 80 and overCD163 AntigenFemaleHumansMaleMiddle AgedAntigens, CDAntigens, Differentiation, MyelomonocyticBiomarkers, TumorCCL2 protein, humanCCL4 protein, humanCD163 AntigenChemokine CCL2Chemokine CCL4Receptors, Cell SurfaceAsymptomatic Waldenstrom’s Macroglobulinemia (AWM)biomarkersCCL2 {Monocyte Chemoattractant Protein-1 (MCP-1)}CCL4 {Macrophage Inflammatory Protein 1 beta (MIP-1b)}prognosissoluble CD163 (sCD163)Tumor-associated macrophages (TAMs)Waldenstrom’s Macroglobulinemia (WM)

Identifiers

PMID39996747
PMCPMC11853255

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.